AmnioGraft®: Treating Ocular Conditions Like Pterygium

Over the years of treating Pterygium patients, Neel Desai, MD developed an effective technique for primary pterygium surgery using AmnioGraft that reduced recurrence rate and surgical time with little to no pain reported.

Fill out the contact form and download the free surgical guide.

AmnioGraft, an amniotic membrane graft, helps rapidly restore the healthy ocular surface when used during ocular surface reconstruction surgery, especially with pterygium and conjunctivochalasis (CCh) procedures. Delivering the unique therapeutic advantage of cryopreserved amniotic membrane tissue, AmnioGraft can help your patients achieve superior cosmetic outcomes and maximize longterm results.^3,4,6,7

Discover AmnioGraft^® 

A transplantation graft used by ophthalmologists around the world to manage
ocular surface indications such as corneal ulcers, pterygium, Stevens-Johnson Syndrome, and conjunctivochalasis (CCh).

Support Accelerated Post-Op Recovery¹

AmnioGraft^® expedites patient recovery by reducing inflammation^5,9-11 and promoting fast, regenerative healing – typically within 2-3 weeks^1-7. It helps prevents disease recurrence ^1,2,6-8 as demonstrated in a study of 535 patients. AmnioGraft creates a durable recurrence barrier proven to support sustained healing with ≤5.8%* recurrence after 1 year¹.

Creating a Healing Environment

AmnioGraft contains the only cryopreserved amniotic membrane that is FDA-cleared and designated for anti-inflammation, anti-scarring and anti-angiogenesis. Proprietary CryoTek preservation method retains the biologic properties and structural integrity is equivalent to fresh tissue^2,12.

“Dry eye disease isn’t just simply a problem with quantitative tear film, meaning a low tear volume. Dry eye can also be from an abnormal tear film where you have tears, but they’re either unhealthy, or they’re not getting to the location that they need to, and one of the classic examples is what we call ‘Conjunctivochalasis’ or Mechanical Dry Eye.”

“We’ve all had the paradoxical patient that seems to have dry eye and typical ocular surface disease, but they simply don’t respond to all of the typical conventional therapies…there is a missing x-factor. And that x-factor is this Mechanical Dry Eye concept, or conjunctivochalasis.”

“Mechanical Dry Eye is rampant; it’s almost ubiquitous in individuals over the Medicare age of 65, and we have to look for it. The key is making the diagnosis. I get fooled still. I look, white light shining the slit beam across, and I’m thinking to myself, ‘Oh, there’s not a whole lot of redundant conjunctiva here.’ I put the fluorescein in, I turn on the cobalt blue light, and then even better, I put a yellow filter on the other side of the microscope, and it highlights the redundant fold of the conjunctiva.”